199599-68-3

Basic information

• Product Name: 4-Thiazolecarboxaldehyde, 2-[(dimethylamino)methyl]-
• Synonyms: 2-dimethylaminomethylthiazole-4-carboxaldehyde;2-dimethylaminomethylthiazole-4-carboxyaldehyde
• CAS NO: 199599-68-3
• Molecular Formula: C7H10N2OS
• Molecular Weight: 170.235
• Mol File: 199599-68-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 253.9±20.0 °C(Predicted)
• Density: 1.212±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 4-Thiazolecarboxaldehyde, 2-[(dimethylamino)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Thiazolecarboxaldehyde, 2-[(dimethylamino)methyl]-(199599-68-3)
• EPA Substance Registry System: 4-Thiazolecarboxaldehyde, 2-[(dimethylamino)methyl]-(199599-68-3)

Safety Data

• Hazardous Substances Data: 199599-68-3(Hazardous Substances Data)

Upstream product

• 78441-69-7 2-dimethylaminomethyl-4-hydroxymethylthiazole 
• 87413-09-0 Dess-Martin periodane 
• 82586-66-1 ethyl 2-(dimethylaminomethyl)-4-thiazolecarboxylate 
• 70-23-5 ethyl Bromopyruvate 
• 27366-72-9 2-dimethylaminothioacetamide hydrochloride 

Relevant articles and documents

Synthesis of New 1,3-Thiazolecarbaldehydes

H-Lithiation and Br-lithiation reactions of 1,3-thiazole were studied in order to obtain new thiazole derivatives. Four isomeric chloromethyl derivatives of 1,3-thiazole containing a protected aldehyde group like 2-(1,3-dioxolan-2-yl)-5-(chloromethyl)-1,3-thiazole, 5-(1,3-dioxolan-2-yl)-2-(chloromethyl)-1,3-thiazole, 4-(1,3-dioxolan-2-yl)-2-(chloromethyl)-1,3-thiazole, and 2-(1,3-dioxolan-2-yl)-4-(chloromethyl)-1,3-thiazole were synthesized. Their nucleophilic substitution reactions with dimethylamine and sodium methylthiolate were studied. New aldehydes of 1,3-thiazole series of low-molecular weight were obtained.

Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones

The present invention relates to novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.

Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones

From EXEMP_CLAIMS : 1. A bicyclic compound of the formula wherein ring positions ""F"" and ""G"" may be independently selected from carbon, nitrogen, oxygen or sulfur, and J is independently selected from carbon, nitrogen or oxygen with the proviso that: i) if more than two of ""F"", ""G"" or ""J"" is a heteroatom then said 5 membered heteroaromatic ring is selected from the group consisting of (1,2,3)-triazole, (1,2,3)-thiadiazole, (1,2,5)-thiadiazole, and (1,2,5)-oxadiazole; and ii) if two of ""F"", ""G"" or ""J"" are heteroatoms, one of said heteroatoms may be oxygen or sulfur; wherein said fused heteroaromatic rings may optionally be independently substituted on any of the carbon or nitrogen atoms capable of forming an additional bond with a substituent selected from hydrogen, (C1-C6)alkyl, halogen, trifluoromethyl, amino-(CH2)n-, (C1-C6)alkylamino-(CH2)p-, di(C1-C6)alkyl-amino-(CH2)n-, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkyl-O-(C1-C6)alkyl-, -CN, hydroxy,-NO2, R3-C(=O)-, R4-O-C(=O)-, di(C1-C6)alkyl-N-C(=O)-, (C1-C6)cycloalkyl, and R4-NH-C(=O)-, and phenyl optionally substituted with halo, (C1-C6) alkyl, -CN, or -CF3; R1 is substituted phenyl of the formula Ph1 or heteroaryl wherein said heteroaryl is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, wherein said heteroaryl may optionally be substituted on any of the atoms capable of forming an additional bond, up to a maximum of three substituents, with a substituent selected from hydrogen, (C1-C6)alkyl, halogen, trifluoromethyl, amino-(CH2)n-, (C1-C6)alkylamino-(CH2)n-, di(C1-C6)alkyl-amino-(CH2)n-, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkyl-O-(C1-C6)alkyl-, -CN, hydroxy, H-C(=O)-, (C1-C6)alkyl-C(=O)-, HO-C(=O)-, (C1-C6)alkyl-O-C(=O)-, NH2-C(=O)-, (C1-C6)alkyl-NH-C(=O)-, (=O)-, and di(C1-C6)alkyl-NH-C(=O)-; wherein said Ph1 is a group of the formula R2 is disubstituted phenyl of the formula Ph2 or a five or six membered heterocycle, wherein said 6-membered heterocycle has the formula wherein ""N"" is nitrogen; wherein said ring positions ""K"", ""L"" and ""M"" may be independently selected from carbon or nitrogen, with the proviso that only one of ""K"", ""L"" or ""M"" can be nitrogen; wherein said five membered heterocycle has the formula wherein said ring positions ""P,"" ""Q"" and ""T"" may be independently selected from carbon, nitrogen, oxygen or sulfur; with the proviso that only one of ""P,"" ""Q"" or T can be oxygen or sulfur and at least one of ""P,"" ""Q"" or ""T"" must be a heteroatom; wherein said Ph2 is a disubstituted group of the formula R3 is hydrogen or (C1-C6) alkyl; R4 is hydrogen or (C1-C6) alkyl; R5 is hydrogen (C1-C6)alkyl, halo, CF3, (C1-C6)alkoxy or (C1-C6)alkylthiol; R6 is hydrogen or halo; R7 is hydrogen or halo; R8 is hydrogen or halo; R9 is hydrogen, (C1-C6)alkyl optionally substituted with one to three halogen atoms, halo, CF3, [C1-C6)alkoxy optionally substituted with one to three halogen atoms, (C1-C6)alkylthiol, R13O-(CH2)p-, (C1-C6)alkyl-NH-(CH2)p-, di(C1-C6)alkyl-N-(CH2)n-, (C1-C5)cycloalkyl-NH-(CH2)p-, H2N-(C=O)-(CH2)p-, (C1-C6)alkyl-HN-(C=O)-(CH2)p-, di(C1-C6)alkyl-N-(C=O)-(CH2)p-, (C1-C5)cycloalkyl-NH-(C=O)-(CH2)p-R13O-(C=O)-(CH2)p-(C1-C6)alkyl-(O=C)-O-(C1-C6)-alkyl-, (C1-C6)alkyl-O-(O=C)-O-(C1-C6)-alkyl-, (C1-C6)alkyl(O=C)-O-, (C1-C6)alkyl-(O=C)-NH-(CH2)p-, H(O=C)-NH-(CH2)p-, hydroxy, H-C(=O)-(CH2)p-, (C1-C6)alkyl-C(=O)-, (C1-C6)alkyl-O-C(=O)-, R4-(CH2)p-O-C(=O)-, amino-(CH2)p-, hydroxy-(C1-C6)alkyl-, (C1-C6)alkyl-O-(C1-C6)alkyl-, and -CN; R10 and R14 are hydrogen, (C1-C6)alkyl optionally substituted with one to three halogen atoms, halo, CF3, (C1-C6)alkoxy optionally substituted with one to three halogen atoms, (C1-C6)alkyl-NH-(CH2)p-, (C1-C6)alkyl-NH-(CH2)p-, di(C1-C6)alkyl-N-(CH2)p-, (C1-C5)cycloalkyl-NH-(CH2)p-, H2N-(C=O)-(CH2)p-, (C1-C6)alkyl-HN-(C=O)-(CH2)p-, di(C1-C6)alkyl-N-(C=O)-(CH2)p-, (C1-C5)cycloalkyl-NH-(C=O)-(CH2)p-, R13O-(C=O)-(CH2)p-, (C1-C6)alkyl-(O=C)-O-(C1-C6)alkyl-, (C1-C6)alkyl-O-(O=C)-O-(C1-C6)-alkyl-, (C1-C6)alkyl-(O=C)-O-, (C1-C6)alkyl-(O=C)-NH-(CH2)p-, H(O=C)-NH-(CH2)p-, hydroxy, H-C(=O)-(CH2)p-, (C1-C6)alkyl-C(=O)-, (C1-C6)alkyl-O-C(=O)-, R4-(CH2)p-O-C(=O)-, amino-(CH2)p-, hydroxy-(C1-C6)alkyl, (C1-C6)alkyl-O-(C1-C6)alkyl. -CHO and -CN; R11 is hydrogen or halo; R12 is hydrogen or halo; R13 is hydrogen, (C1-C6)alkyl, (C1-C6)alkyl-(C=O)-, (C1-C6)alkyl-O-(C=O)-, (C1-C6)alkyl-O-(C=O)-, or di(C1-C6)alkyl-N-(C=O)-; R15 is hydrogen, -CN, (C1-C6) alkyl, halo, CF3, -CHO or (C1-C6)alkoxy; R16 is hydrogen, -CN, (C1-C6)alkyl, halo, CF3, -CHO or (C1-C6)alkoxy; R17 is hydrogen, -CN, (C1-C6)alkyl, halo, CF3, CHO or (C1-C6)alkoxy; n is an integer from zero to 3; p is an integer from zero to 3; wherein the dashed bond represented an optional double bond; with the proviso that when R9 is hydrogen, then one of R11 and R12 is other than hydrogen; and the pharmaceutically acceptable salts of such compounds.